### Weight Loss Medications: A New Hope for Obesity For many of the 42 million Americans struggling with obesity, weight loss medications like Wegovy, Saxenda, and the new Zepbound offer a promising solution. These medications, known as GLP-1 agonists, work by activating hormone receptors that make you feel full, leading to significant weight loss. Some patients have experienced up to a 22% reduction in body weight. However, accessing these medications has been challenging. High costs, sometimes reaching $1,300 per month without insurance, and shortages have been major barriers. Eli Lilly's new direct-to-patient portal, LillyDirect, aims to address these issues by offering medications at lower costs, as little as $25 per month for those with commercial insurance. LillyDirect allows patients to access these medications through a telehealth platform called FORM, where they can consult with independent telehealth providers. This service is seen as a significant step towards making these life-changing medications more accessible and affordable. Research has shown that GLP-1 medications not only aid in weight loss but also reduce the risk of cardiovascular issues like heart attacks and strokes. This has led to calls for broader insurance coverage, including Medicare and Medicaid, to make these treatments available to more people. Experts emphasize that obesity, like other chronic conditions, requires continuous treatment. Stopping the medication often leads to weight regain, so long-term use is generally necessary. Comprehensive insurance coverage could also reduce the risk of patients turning to unreliable sources for these medications. In summary, while weight loss medications like Wegovy, Saxenda, and Zepbound offer significant benefits for those struggling with obesity, making them accessible and affordable remains a challenge. Initiatives like LillyDirect are a step in the right direction, but broader insurance coverage is essential for long-term success.